Chronic Idiopathic Constipation (CIC) Treatment Market To Witness Strong Growth Due To Rise In Prevalence Of Chronic Constipation
Chronic Idiopathic Constipation (CIC) Treatment
Market
Overview:
Chronic idiopathic
constipation (CIC) is classified as one of the functional gastrointestinal
disorders, meaning that testing does not identify an abnormality in the
digestive system. Management of CIC includes patient education, dietary changes
and laxatives as well as behavior modification. The primary goal of chronic idiopathic
constipation treatment is to improve the bowel movement frequency, ease of
passing stool and control the pain and abdominal discomfort from constipation.
Market Dynamics:
The
growing number of old age population across the globe is expected to propel
growth of the global chronic idiopathic constipation (CIC) treatment market
during the forecast period. Old age population is highly susceptible to
suffering from CIC, as they use analgesics such as hydromorphone, morphine,
codeine like prescription for chronic pain. This in turn affects their digestive
system, due to which they are likely to suffer from CIC. Thus, this factor is
projected to support growth of the market. For instance, as per the World Bank
data, the geriatric population increased from 9.102% in 2019 to 9.321% in 2020,
which is 723,184,486.
However, the
decline in healthcare expenditure in some of the developing countries is
anticipated to hinder growth of the global chronic idiopathic constipation
(CIC) treatment market during the forecast period.
Impact of COVID-19:
The
outbreak of the pandemic affected more than 200 countries across the world, and
as a result the number of patient visits reduced everywhere. Moreover, the
demand for constipation treatment also declined during the pandemic, which
adversely affected growth of the chronic
idiopathic constipation (CIC) treatment market. However, in some of the
COVID-19 infection cases, the need for constipation treatment was emerging. Thus,
the outbreak of COVID-19 and subsequent symptoms of irritable bowel syndrome or
constipation are likely to drive growth of the market in the near future.
Key Takeaways:
·
The global chronic idiopathic constipation (CIC) treatment
market is anticipated to grow with a CAGR of 7.0% during the
forecast period, due to rise in cases of chronic constipation health disorders.
For instance, as per the National Center for Biotechnology Information, the
average prevalence of constipation among adults is estimated as 16% across the
world, and 33.5% of prevalence was among adults aged 60 to 110 years.
·
Among regions, North America is
expected to show significant growth in the global chronic idiopathic
constipation (CIC) treatment market during the forecast period, owing to
growing cases of chronic constipation in the region, and rise in investment in
healthcare sector.
·
Key players functioning in the
global chronic idiopathic constipation (CIC) treatment market are Boehringer
Ingelheim GmbH, Takeda Pharmaceutical Company Ltd., Janssen Pharmaceutical
Company, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Salix
Pharmaceuticals, Inc., Pfizer Inc., Abbott Laboratories, Valeant
Pharmaceuticals International Inc., AstraZeneca Plc, Bayer AG, Cosmo
Pharmaceuticals NV, and Sanofi S.A.
Comments
Post a Comment